This randomized controlled trial compared the effects of metformin and combined oral contraceptives (COCs) in adolescent women with polycystic ovary syndrome (PCOS) over 24 months. 119 adolescent girls were randomly assigned to receive metformin, COCs, or no treatment (control group). Both metformin and COCs significantly improved cycle regularity and hirsutism compared to the control group. However, metformin was associated with significant improvement in insulin sensitivity, while COCs deteriorated insulin sensitivity. The study concludes that metformin and COCs have comparable effects on symptoms, but metformin may have metabolic advantages in adolescent PCOS patients.
Book Paid Powai Call Girls Mumbai 𖠋 9930245274 𖠋Low Budget Full Independent H...
RCT Compares Metformin and COCs in Adolescent PCOS Women Over 24 Months
1. RCT of the effects of
Metformin Vs
COCs
in adolescent
PCOS
women through a 24 month
follow up period
ABOUBAKR ELNASHAR
ABOUBAKR ELNASHAR
2. ADOLESCENT PCOS
Affects a substantial number of girls with
increasing incidence
{increasing prevalence of childhood obesity}
(Hassan et al, 2007).
±Progressive course with the potential to develop
full-blown picture of adult PCOS
(evidence is contradictory)
(Coviello et al, 2006)
ABOUBAKR ELNASHAR
3. Therapeutic goals:
symptomatic and prophylactic:
Restoration of body weight
Cycle regulation
Reducing signs of hyperandrogenism
Prevention of long term health hazards.
Infertility
Metabolic syndrome
Obesity
Diabetes
Heart disease.
ABOUBAKR ELNASHAR
4. Diagnosis:
2 years after menarche
{overlap between normal pubertal development and
characteristic features of PCOS}
Hyperandrogenemia (Serum testosterone >1
µg/ml): the most reliable finding
NIH:
Rotterdam criteria: All 3 OR
(Carmina et al, 2010)
AE-PCOS Society criteria
(Legro et al, 2013).
ABOUBAKR ELNASHAR
6. Management
Lifestyle modification
Weight reduction and excerise
{obesity worsens the endocrine profile of these
women and increases the risk of infertility}
decrease androgen effects
increase ovulation
improve insulin sensitivity.
Metformin
COC
ABOUBAKR ELNASHAR
7. There are few studies comparing COC and Met in
adolescents PCOS
To our knowledge, this study is 1st to follow up
adolescent PCOS women for a period of 2 years.
ABOUBAKR ELNASHAR
8. OBJECTIVE
To compare Met and COC effects over 24 mo in
adolescent PCOS.
Design: RCT
ABOUBAKR ELNASHAR
9. Sample size
of the study groups was calculated
32 patients were required for each study group.
119 adolescent girls
Age: 15–20 years
Hirsutism, acne and menstrual disturbances.
ABOUBAKR ELNASHAR
10. PCOS:
Oligomenorrhoea (<6 cycles/year) and
Serum testosterone >1 µg/ml
Randomization
computer-generated random-number tables:
Group A (n= 40): Met: 1700 mg/d
Group B (n= 40): COC (30 µg EE and150µg desogestrel, Marvelon)
Group C (n= 39): Control.
ABOUBAKR ELNASHAR
11. Initial assessment
B wt, Waist-to-hip ratio, Ferriman–Gallway score,
Total testosterone, FSH, LH, prolactin,
transaminases.
Insulin resistance
75 g OGTT
GIR
Fasting and after load insulin
ABOUBAKR ELNASHAR
12. Outcome measures:
Primray
Improvement in cycle rhythm and hirsutism.
Secondary
Weight loss
Serum testosterone levels
Fasting and after load serum insulin levels
GIR
ABOUBAKR ELNASHAR
13. Control group
(n=39)
Metformin group
(n=40)
OCP group
(n=40)
Control group
(n=35)
Metformin group
(n=37)
OCP group
(n=39)
Control group
(n=32)
Metformin group
(n=36)
OCP group
(n=36)
Control group
(n=29)
Metformin group
(n=33)
OCP group
(n=34)
Analysed
(n=25)
Analysed
(n=32)
Analysed
(n=33)
randomized (n=119)
3 DOs (side effects)
1 DO (side effects)
3 DOs (2 non-compliant, 1
not satisfied with drug)
1 DO (lost for follow up)
1 DO (non-compliant)
3 DOs (weight gain)
2 DOs (1 side effects, 1
weight gain)
1 DO (side effects)
4 DOs (worsening
symptoms asked
for treatment)
3 DOs (2 worsening
symptoms, 1asked for
treatment)
3 DOs (lost for follow
up)
4 DOs (lost for follow
up)
6m
12 m
18 m
24 m
Consort flow chart
ABOUBAKR ELNASHAR
14. A B C
mean SD mean SD mean SD
Age (Years) 17.20 2.00 16.90 1.60 17.00 2.10
Weight (Kgs) 87.00 6.00 91.00 3.00 84.00 6.00
Testosterone (µg/ml) 1.50 0.40 1.30 0.50 1.20 0.40
Fasting Insulin (µIU/L) 18.60 3.00 15.00 3.00 15.00 2.00
After-load Insulin (µIU/L) 126.00 34.0 103.00 19.00 100.00 21.00
GIR 4.10 0.30 4.40 0.20 3.90 0.50
Clinical characteristics of the three study groups
ABOUBAKR ELNASHAR
15. Cycle regularity
Sig improvement in Group A and Group B:
(92.5% and 100%)
compared to the control group
Hirsutism
Subjective improvement in Group A and Group B
(25% and 40%)
compared to the control group
ABOUBAKR ELNASHAR
16. Group
Baseline 6 months 12 months 18 months 24 months
mean SD mean SD mean SD mean SD mean SD
T(µg/ml)
A 1.50 0.40 0.80 0.10 1.10 0.40 1.30 0.30 1.20 0.30
B 1.30* 0.50 1.00 0.30 0.90 0.40 0.60 0.30 0.70* 0.20
C 1.20 0.40 1.30 0.20 1.00 0.20 1.60 0.20 1.50 0.40
Fasting
insulin
(µIU/L)
A 18.60* 3.00 15.00 4.00 14.00 2.00 9.00 2.00 10.00* 3.00
B 15.00 3.00 14.00 2.00 16.00 4.00 21.00 3.00 19.00 4.00
C 15.00 2.00 13.00 3.00 21.00 5.00 20.00 4.00 22.00 3.00
After-load
insulin
(µIU/L)
A 126.00 34.00 100.00 31.00 91.00 21.00 82.00 16.00 64.00* 15.00
B 103.00 19.00 100.00 21.00 135.00 41.00 167.00 34.00 187.00 22.00
C 100.00 21.00 110.00 21.00 133.00 29.00 103.00 37.00 111.00 12.00
GIR
A 4.10* 0.30 4.00 0.30 3.90 0.30 4.80 0.40 4.60* 0.50
B 4.40* 0.20 4.20 0.30 3.60 0.40 3.60 0.30 3.10* 0.30
C 3.90 0.50 3.90 0.30 4.00 0.30 3.50 0.20 3.10 0.30
Weight
(Kg)
A 87.00* 6.00 82.00 8.00 83.00 5.00 79.00 6.00 72.00* 5.00
B 84.00 9.00 87.00 8.00 90.00 9.00 91.00 10.00 91.00 3.00
C 84.00 6.00 91.00 5.00 97.00 8.00 93.00 7.00 99.00 9.00
Follow up parameters for the 3 study groups.
ABOUBAKR ELNASHAR
17. Group A: sig drop from 1.5 to 0.8 µg/ml by 6 mo, by 24 mo
:1.2 µg/ml, which is not significantly different from initial values.
Group B: sig decline from1.3 to 0.7 µg/ml by the end of 24 mo
Group C: non-sig increase from 1.2 to 1.5 µg/ml.
ABOUBAKR ELNASHAR
18. Group A: sig increase from 4.1 to 4.6 {improvement in insulin sensitivity}
Group B: sig decrease from 4.4 to 3.1 {deteriorating insulin sensitivity}.
Group C: non sig decrease from 3.9 to 3.1ABOUBAKR ELNASHAR
19. Group A: sign decline from 87 to 72 kg
Group B: non-significant gain from 84 to 91 kg
Group C: non-significant gain from 84 to 99 kg
ABOUBAKR ELNASHAR
20. Group A: sign decline from 126 to 64 µIU/L
Group B: sig increase from 103 to 187 µIU/L
Group C: non sig increase from 100 to 111 µIU/L
ABOUBAKR ELNASHAR
21. Cochrane SR, 2007
After 12 mo;
No difference in the therapeutic effectiveness
between Met and COC on hirsutism and acne,
but Met resulted in a reduction in fasting insulin
and lower triglyceride levels than COC.
ABOUBAKR ELNASHAR
22. CONCLUSIONS
Met and COC have comparable therapeutic
effectiveness on cycle regularity and hirsutism.
Met was associated with a sig improvement in
insulin sensitivity
COC was associated with a deterioration of
insulin sensitivity
ABOUBAKR ELNASHAR
23. RECOMMENDATION
The choice of the proper line of therapy should be
tailored for every patient, according to
Age
Stage in life
Symptoms
Personal and familial risk indices
Choices.
ABOUBAKR ELNASHAR
24. If the main complaints are limited to acne and
hirsutism:
Met is advantageous having a safer profile than
COC.
If the main aim is menstrual cycle control:
COC have clear advantages in terms of
effectiveness and cost.
ABOUBAKR ELNASHAR